TABLE 5.
Quality of life assessed by NEI VFQ-25, high = well).
| IVT-AFL (2mg, bi-monthly) versus Laser | ||||||
|---|---|---|---|---|---|---|
| Item | Follow-up | Study ID | Sample Size | MD | 95% CI | p-Value |
| Subscale (near activities) score | 1-year | Chen 2020 | 251 | 6.87 | 0.48 to 13.26 | 0.04 |
| 100-week | Brown 2015-VISTA | 305 | 4.7 | −0.18 to 9.58 | 0.08* | |
| Brown 2015-VIVID | 267 | 2.2 | Not reported | >0.05** | ||
| Subscale (distance activities) score | 1-year | Chen 2020 | 251 | 8.01 | 2.36 to 13.66 | 0.005 |
| 100-week | Brown 2015-VISTA | 305 | 2.4 | Not reported | >0.05** | |
| Brown 2015-VIVID | 267 | 2.7 | Not reported | >0.05** | ||
| IVT-AFL (2mg, monthly) versus Laser | ||||||
| Item | Follow-up | Study ID | Sample Size | MD | 95% CI | p -Value |
| Subscale (near activities) score | 1-year | Chen 2020 | 251 | 5.78 | −0.71 to 12.27 | 0.08* |
| 100-week | Brown 2015-VISTA | 308 | 2.8 | Not reported | >0.05** | |
| Brown 2015-VIVID | 268 | 3.4 | Not reported | >0.05** | ||
| Subscale (distance activities) score | 1-year | Chen 2020 | 251 | 2.82 | −3.08 to 8.72 | 0.35 |
| 100-week | Brown 2015-VISTA | 308 | 4.8 | 0.05 to 9.55 | 0.05* | |
| Brown 2015-VIVID | 268 | 2.4 | Not reported | >0.05** | ||
| IVR (0.5mg, 3+PRN) versus Laser | ||||||
| Item | Follow-up | Study ID | Sample Size | MD | 95% CI | p -Value |
| Composite score | 1-year | Berger 2015 | 147 | 6 | 2.7 to 9.4 | <0.001 |
| Mitchell 2011 | 227 | 4.4 | Not reported | 0.014 | ||
| Subscale (general vision) score | Mitchell 2011 | 227 | 7.8 | Not reported | <0.001 | |
| Subscale (near activities) score | Mitchell 2011 | 227 | 7.9 | Not reported | <0.001 | |
| Subscale (distance activities) score | Mitchell 2011 | 227 | 4.9 | Not reported | <0.001 | |
| IVC (0.5mg, 1+PRN) versus Laser | ||||||
| Item | Follow-up | Study ID | Sample Size | MD | 95% CI | p -Value |
| Composite score | 1-year | Liu 2021 | 248 | 8.1 | 3.47 to 12.73 | 0.0006 |
MD was calculated using RevMan 5.4 when necessary. *Significant differences were identified in the original trials. **No significant differences were identified in the original trials.
Notes: 1) general vision was defined as eyesight now (with glasses or contact lenses, if wear them). Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf. Distance activities are defined as reading street signs or names on stores, and going downstairs, steps, or curbs. 2) 12 months or 52 weeks were considered as one year. Statistically, significance was presented in bold italic format. CI, confidence interval; IVB, intravitreal bevacizumab; IVC, intravitreal conbercept; IVR, intravitreal ranibizumab; IVT-AFL, intravitreal aflibercept; MD, mean difference; NEI VFQ-25, National Eye Institute Visual Function Questionnaire-25 item; PRN, pro re nata.